title: [The relationship between inflammation and symptoms in asthma].
abstract: In asthma, symptoms are the main reason for recourse to healthcare and are a fundamental parameter for the evaluation of asthma control. Currently, asthma is defined as a chronic inflammatory disease. Uncontrolled asthmatics have an increased number of eosinophils in induced sputum and an increased production of exhaled NO. Control by anti-inflammatory treatment is accompanied by a reduction in bronchial eosinophilia and exhaled NO. Asthma symptoms are the result of complex mechanisms and many factors modify their perception. Experimental data suggests that there is a relationship between the perception of symptoms and eosinophilic inflammation, and that inhaled corticoid therapy improves this perception. Although they are still not applicable in routine practice, follow-up strategies based on the evaluation of inflammation are thought to be more effective in reducing exacerbations than those usually recommended based on retrospective evaluation of symptoms and sequential analysis of respiratory function. Inhaled corticosteroid therapy is the reference maintenance therapy for persistent asthma and adjustment of anti-inflammatory treatment based on symptoms is an effective strategy to prevent exacerbations and reduce the total dose of inhaled corticosteroids. A French expert group has undertaken a study of the association between inflammation and asthma symptoms by carrying out a critical review of the international literature.
authors.affiliation: Université Paris-Sud 11, Hôpital Antoine Béclère, Clamart, France. david.montani@abc.aphp.fr
authors.forename: D
authors.initials: D
authors.lastname: Montani
authors.forename: I
authors.initials: I
authors.lastname: Tillie-Leblond
authors.forename: B
authors.initials: B
authors.lastname: Crestani
authors.forename: J
authors.initials: J
authors.lastname: De Blic
authors.forename: M
authors.initials: M
authors.lastname: Humbert
authors.forename: M
authors.initials: M
authors.lastname: Tunon-De-Lara
authors.forename: A
authors.initials: A
authors.lastname: Magnan
authors.forename: N
authors.initials: N
authors.lastname: Roche
authors.forename: S
authors.initials: S
authors.lastname: Gati
authors.forename: P
authors.initials: P
authors.lastname: Chanez
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D004802:Eosinophilia / Q000503:physiopathology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology*; D009569:Nitric Oxide / Q000378:metabolism; D015656:Respiratory Mechanics
chemical_list: D000893:Anti-Inflammatory Agents; D009569:Nitric Oxide